Recombinant Human Anti-SCARB1 Antibody (mAb8) (CAT#: HPAB-1609-FY)

Figure 1 Anti-SR-BI mAb8 and mAb151 interfere with direct cell-to-cell transmission of HCV in vitro.

The effect of mAb8 and mAb151 on direct cell-to-cell transmission of HCV was investigated by combining Huh-7.5-RFPNLS-IPS target cells with Jc1-transfected Huh-7.5-EGFP-IPS cells. These cocultures were pretreated with increasing concentrations of mAb8 and 151 (0; 0.2; 2; 20 μg/ml) in the presence of a neutralizing anti-HCV antibody (nAb, 150 μg/ ml).

Lacek, K., Vercauteren, K., Grzyb, K., Naddeo, M., Verhoye, L., Słowikowski, M. P., ... & Leroux-Roels, G. (2012). Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. Journal of hepatology, 57(1), 17-23.

Figure 2 Neutralization of J6/JFH1 HCVcc infection by anti-SR-Bl mAbs.

Huh7.5 cells were infected with HCVcc upon pre-incubation with increasing concentrations (ng/ml) of anti-SR-Bl mAbs. Infectivity was measured 3 days post-infection.

Figure 3 Efficacy of mAb8 in prevention mode: mAb8 can prevent HCV infection in vivo.

Figure 4 Efficacy of mAb8 in post-exposure therapeutic mode: mAb8 reduces HCV post exposure in vivo.

Figure 5 Apparent affinity of anti-SRBl mAbs.

Figure 6 Binding to CHO/SR-BI cells and HCVcc inhibitory properties of various anti-SR-BI mAbs.

CHO/SR-BI and parental CHO cells were incubated for 1 h with 10 μg/ml of various anti-SR-BI antibodies or control, isotype-matched human IgG. Binding was revealed by allophycocyanin-conjugated goat anti-human IgG and subsequent flow cytometry analysis.

Lacek, K., Vercauteren, K., Grzyb, K., Naddeo, M., Verhoye, L., Słowikowski, M. P., ... & Leroux-Roels, G. (2012). Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. Journal of hepatology, 57(1), 17-23.